{
    "title": "Drug Interaction Vectors Neural Network: DrIVeNN. (arXiv:2308.13891v1 [cs.LG])",
    "abstract": "Polypharmacy, the concurrent use of multiple drugs to treat a single condition, is common in patients managing multiple or complex conditions. However, as more drugs are added to the treatment plan, the risk of adverse drug events (ADEs) rises rapidly. Many serious ADEs associated with polypharmacy only become known after the drugs are in use. It is impractical to test every possible drug combination during clinical trials. This issue is particularly prevalent among older adults with cardiovascular disease (CVD) where polypharmacy and ADEs are commonly observed. In this research, our primary objective was to identify key drug features to build and evaluate a model for modeling polypharmacy ADEs. Our secondary objective was to assess our model on a domain-specific case study. We developed a two-layer neural network that incorporated drug features such as molecular structure, drug-protein interactions, and mono drug side effects (DrIVeNN). We assessed DrIVeNN using publicly available sid",
    "link": "http://arxiv.org/abs/2308.13891",
    "context": "Title: Drug Interaction Vectors Neural Network: DrIVeNN. (arXiv:2308.13891v1 [cs.LG])\nAbstract: Polypharmacy, the concurrent use of multiple drugs to treat a single condition, is common in patients managing multiple or complex conditions. However, as more drugs are added to the treatment plan, the risk of adverse drug events (ADEs) rises rapidly. Many serious ADEs associated with polypharmacy only become known after the drugs are in use. It is impractical to test every possible drug combination during clinical trials. This issue is particularly prevalent among older adults with cardiovascular disease (CVD) where polypharmacy and ADEs are commonly observed. In this research, our primary objective was to identify key drug features to build and evaluate a model for modeling polypharmacy ADEs. Our secondary objective was to assess our model on a domain-specific case study. We developed a two-layer neural network that incorporated drug features such as molecular structure, drug-protein interactions, and mono drug side effects (DrIVeNN). We assessed DrIVeNN using publicly available sid",
    "path": "papers/23/08/2308.13891.json",
    "total_tokens": 905,
    "translated_title": "药物相互作用向量神经网络: DrIVeNN",
    "translated_abstract": "多药并用是治疗单一病症常见的方法，特别是对于管理多种或复杂病症的患者来说。然而，随着药物方案中增加药物的数量，不良药物事件（ADEs）的风险迅速上升。许多与多药并用相关的严重ADEs只有在药物使用后才会被发现。在临床试验中测试每种可能的药物组合是不可行的。这个问题在老年心血管疾病（CVD）患者中尤为常见，多药并用和ADEs常常观察到。本研究的主要目标是确定建立和评估多药并用ADEs模型的关键药物特征。我们的次要目标是在特定领域案例研究中评估我们的模型。我们开发了一个包括分子结构、药物-蛋白相互作用和单药副作用等药物特征的两层神经网络（DrIVeNN）。我们使用公开可用的sid进行了DrIVeNN的评价。",
    "tldr": "本研究开发了一个名为DrIVeNN的两层神经网络，该网络通过整合药物特征，如分子结构、药物-蛋白相互作用和单药副作用等来建立和评估多药并用不良药物事件（ADEs）模型。"
}